JP2008545616A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545616A5
JP2008545616A5 JP2007555704A JP2007555704A JP2008545616A5 JP 2008545616 A5 JP2008545616 A5 JP 2008545616A5 JP 2007555704 A JP2007555704 A JP 2007555704A JP 2007555704 A JP2007555704 A JP 2007555704A JP 2008545616 A5 JP2008545616 A5 JP 2008545616A5
Authority
JP
Japan
Prior art keywords
dopa
dopamine agonist
medicament
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007555704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545616A (ja
Filing date
Publication date
Priority claimed from GB0503540A external-priority patent/GB0503540D0/en
Priority claimed from GB0508843A external-priority patent/GB0508843D0/en
Application filed filed Critical
Priority claimed from PCT/GB2006/000583 external-priority patent/WO2006087577A2/en
Publication of JP2008545616A publication Critical patent/JP2008545616A/ja
Publication of JP2008545616A5 publication Critical patent/JP2008545616A5/ja
Withdrawn legal-status Critical Current

Links

JP2007555704A 2005-02-21 2006-02-20 ジスキネジーの阻害または治療 Withdrawn JP2008545616A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0503540A GB0503540D0 (en) 2005-02-21 2005-02-21 Inhibition or treatment of dyskinesia
GB0508843A GB0508843D0 (en) 2005-04-29 2005-04-29 Inhibition or treatment of dyskinesia
PCT/GB2006/000583 WO2006087577A2 (en) 2005-02-21 2006-02-20 Inhibition or treatment of dyskinesia

Publications (2)

Publication Number Publication Date
JP2008545616A JP2008545616A (ja) 2008-12-18
JP2008545616A5 true JP2008545616A5 (https=) 2009-04-09

Family

ID=36691702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007555704A Withdrawn JP2008545616A (ja) 2005-02-21 2006-02-20 ジスキネジーの阻害または治療

Country Status (6)

Country Link
US (1) US20080070952A1 (https=)
EP (1) EP1850838A2 (https=)
JP (1) JP2008545616A (https=)
CA (1) CA2598484A1 (https=)
SG (1) SG160342A1 (https=)
WO (1) WO2006087577A2 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9902455A3 (en) * 1996-03-29 2000-06-28 Pfizer 6-phenylpyridyl-2-amine derivatives, pharmaceutical compositions containing them
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina
CN1523015A (zh) * 1997-02-10 2004-08-25 �Ʒ� 2-氨基-6-(2-取代的-4-苯氧基)取代的吡啶类化合物
AU7246398A (en) * 1997-04-30 1998-11-24 Northwestern University Inhibition of nitric oxide synthase by amino acids and dipeptides
AU2002350575A1 (en) * 2001-06-22 2003-01-08 Northwestern University Selective neuronal nitric oxide synthase inhibitors
US20030232739A1 (en) * 2001-08-15 2003-12-18 Pfizer Inc. Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
DOP2002000467A (es) * 2001-10-10 2003-04-15 Pfizer Prod Inc 2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US6803470B2 (en) * 2001-10-10 2004-10-12 Pfizer Inc 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
US7470790B2 (en) * 2003-09-08 2008-12-30 Northwestern University Heteroaromatic selective inhibitors of neuronal nitric oxide synthase

Similar Documents

Publication Publication Date Title
EP2444072A3 (en) Non-mucoadhesive film dosage forms
JP2013505282A5 (https=)
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
WO2008011426A3 (en) Methods and medicaments for administration of ibuprofen
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2008064192A3 (en) Modified release analgesic suspensions
JP2008044951A5 (https=)
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
JP2013541583A5 (https=)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
CL2007002574A1 (es) Composicion farmaceutica oral que comprende levodopa en una dosis unitaria de alrededor de 100 hasta alrededor de 500 mg y un excipiente adecuado; y su uso para tratar parkinson.
JP2013536837A5 (https=)
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX338975B (es) Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria.
TNSN08506A1 (en) Substituted carboxamides
JP2011500589A5 (https=)
RU2008134143A (ru) Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения
NZ591328A (en) Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина